Jeff is the Chairman of the Board of Directors at Lykos Therapeutics. He is the managing partner of Maytal Capital, a healthcare-focused private equity and venture capital firm he founded in 2017, and a partner at Bridge Builders Collaborative, an early-stage venture firm focused on mental health. He was previously global CEO for Sandoz and Alcon at Novartis Group (NYSE: NVS), where he served on the executive committee between 2008 and 2016.
In addition to our board, Jeff serves on the Board of Directors of Amneal Pharmaceuticals, a leader in specialty and generic pharmaceuticals with over $2 billion in revenues (NASDAQ: AMRX); 908 Devices (NASDAQ: MASS), a high-growth pioneer in life science diagnostics; and Dorian Therapeutics, a Silicon Valley-based cellular senescence biotech spun out of Stanford University. He also serves on several non-profit boards and previously served as Chairman of Education Opens Doors between 2019 and 2023.
Between 2008 and 2016, Jeff served on the executive committee of Switzerland-based Novartis Group, first as the global Division Head and CEO of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharma and biosimilar subsidiary, and then as Division Head and CEO of Texas-based Alcon, Novartis’s $10 billion revenue eye care division, which was spun out from Novartis as a publicly listed firm in 2019 (NYSE: ALC). At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 people across more than 160 countries and had leadership responsibility for all functions, regions and franchises.
Prior to these roles, Jeff headed emerging markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals and as vice president and head of Western and Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a senior director of strategic planning and business development at Gap Inc. and an engagement manager with McKinsey & Co., both in San Francisco.
Jeff holds an M.B.A. from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff currently serves as the Chairman of the Board of Directors of Lenz Therapeutics, a publicly traded ophthalmic pharmaceutical company, and as a Board Trustee at Breck School, his high school alma mater in Minneapolis. Jeff previously served on the Board of Directors of AdvaMed, Roam Analytics, and Wishbone Medical. He has lived in seven countries on four continents and currently lives with his wife and two daughters in Dallas.